While the Windows maker did not attribute the activity to a specific threat actor, the use of VS Code tasks and Vercel ...
The Microsoft Defender team has discovered a coordinated campaign targeting software developers through malicious repositories posing as legitimate Next.js projects and technical assessment materials, ...
A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Market researchers expect strong growth in AI infrastructure in 2026, while rising storage prices will dampen demand for end devices. Faster, bigger, smarter — the efforts of manufacturers and ...
Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...
Hosted on MSN
Who really owns JavaScript and why it’s a problem
This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...
A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...
Based on the iconic 1986 novel by Stephen King and serving as a prequel to the 2017 and 2019 “It” films, HBO’s “It: Welcome to Derry,” created by Andy Muschietti, Barbara Muschietti and Jason Fuchs, ...
The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results